StockNews.com Initiates Coverage on Lipocine (NASDAQ:LPCN)

Investment analysts at StockNews.com started coverage on shares of Lipocine (NASDAQ:LPCN) in a research note issued to investors on Saturday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Lipocine Trading Up 3.3 %

LPCN opened at $4.69 on Friday. The business’s 50 day moving average is $4.82 and its 200-day moving average is $4.87. The stock has a market cap of $25.09 million, a PE ratio of -6.17 and a beta of 1.23. Lipocine has a twelve month low of $3.20 and a twelve month high of $11.79.

Lipocine (NASDAQ:LPCN) last announced its quarterly earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter. As a group, analysts forecast that Lipocine will post -0.78 EPS for the current year.

Hedge Funds Weigh In On Lipocine

A hedge fund recently bought a new stake in Lipocine stock. Dimensional Fund Advisors LP acquired a new stake in Lipocine Inc. (NASDAQ:LPCN) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned approximately 0.22% of Lipocine at the end of the most recent reporting period. Institutional investors own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.